Related references
Note: Only part of the references are listed.T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma
Alexander X. Lozano et al.
NATURE MEDICINE (2022)
Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response
Fei-Fei Hu et al.
BRIEFINGS IN BIOINFORMATICS (2021)
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy
Rajasekharan Somasundaram et al.
NATURE COMMUNICATIONS (2021)
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Kevin Litchfield et al.
CELL (2021)
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer
Ayse Bassez et al.
NATURE MEDICINE (2021)
MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING
Yong Zhang et al.
CANCER DISCOVERY (2021)
The N6-Methyladenosine-Modified Pseudogene HSPA7 Correlates With the Tumor Microenvironment and Predicts the Response to Immune Checkpoint Therapy in Glioblastoma
Rongrong Zhao et al.
FRONTIERS IN IMMUNOLOGY (2021)
Investigating Mechanisms of Response or Resistance to Immune Checkpoint Inhibitors by Analyzing Cell-Cell Communications in Tumors Before and After Programmed Cell Death-1 (PD-1) Targeted Therapy: An Integrative Analysis Using Single-cell RNA and Bulk-RNA Sequencing Data
Yi-Quan Jiang et al.
ONCOIMMUNOLOGY (2021)
TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment
Dongqing Sun et al.
NUCLEIC ACIDS RESEARCH (2021)
Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
Imran G. House et al.
CLINICAL CANCER RESEARCH (2020)
ImmuCellAI: A Unique Method for Comprehensive T-Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy
Ya-Ru Miao et al.
ADVANCED SCIENCE (2020)
TIMER2.0 for analysis of tumor-infiltrating immune cells
Taiwen Li et al.
NUCLEIC ACIDS RESEARCH (2020)
Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
Ying Jing et al.
NATURE COMMUNICATIONS (2020)
Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapy
Yixiao Zhang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
ComBat-seq: batch effect adjustment for RNA-seq count data
Yuqing Zhang et al.
NAR GENOMICS AND BIOINFORMATICS (2020)
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
Tuba N. Gide et al.
CANCER CELL (2019)
Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype
Daehwan Kim et al.
NATURE BIOTECHNOLOGY (2019)
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Seung Tae Kim et al.
NATURE MEDICINE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Peng Jiang et al.
NATURE MEDICINE (2018)
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
Noam Auslander et al.
NATURE MEDICINE (2018)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
Pornpimol Charoentong et al.
CELL REPORTS (2017)
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz et al.
CELL (2017)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro et al.
LANCET ONCOLOGY (2016)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
limma powers differential expression analyses for RNA-sequencing and microarray studies
Matthew E. Ritchie et al.
NUCLEIC ACIDS RESEARCH (2015)
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Yang Liao et al.
BIOINFORMATICS (2014)
ImmPort: disseminating data to the public for the future of immunology
Sanchita Bhattacharya et al.
IMMUNOLOGIC RESEARCH (2014)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
GSVA: gene set variation analysis for microarray and RNA-Seq data
Sonja Haenzelmann et al.
BMC BIOINFORMATICS (2013)
Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events
Vafa Shahabi et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The Sequence Alignment/Map format and SAMtools
Heng Li et al.
BIOINFORMATICS (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Share Paper
